Date: Monday, October 22, 2018
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Psoriatic arthritis (PsA) is an inflammatory condition of peripheral joints. If left untreated, it can lead to significant pain and joint deformity. Its treatment has undergone a revolution with the advent of TNF inhibitors and non-TNF biologics. Generally, these agents are well tolerated but due to their immunosuppressive
We conducted a systematic review and random-effects network meta-analysis of randomized clinical trials in STATA 15.1 assessing the occurrence of serious infections with the use of TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab) and non-TNF biologics (apremilast, secukinumab,
2,052 citations were identified and on reviewing full-text papers 16 randomized clinical trials (n=4705) met our inclusion criteria. Based on 12 to 24-week placebo-controlled follow-up data, we identified seven trials using TNF inhibitors (infliximab, adalimumab, certolizumab
TNF inhibitors were not found to confer a higher risk of serious infection than non-TNF biologics. These results provide a better understanding of the risk of serious infection from psoriatic arthritis pharmacotherapy in patients.
To cite this abstract in AMA style:Malik SU, Muzaffar K, Bilal J, Faridi W, Muddassir S. Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/serious-infections-among-psoriatic-arthritis-patients-taking-tnf-inhibitors-versus-non-tnf-biologics-a-systematic-review-and-network-meta-analysis/. Accessed January 18, 2020.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/serious-infections-among-psoriatic-arthritis-patients-taking-tnf-inhibitors-versus-non-tnf-biologics-a-systematic-review-and-network-meta-analysis/